Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mark Marcellus who wrote (4098)	3/11/2002 11:31:30 PM
From: Mike M	Read Replies (1) \| Respond to of 5582

Mark, I'll grant you a couple brand names were mentioned....but,"fairly comprehensive" is a bit of an overstatement. Other products such as zinc lozenges and echinacea were also omitted. Doesn't mean they aren't commonly used. The sin of omission by this source is duly noted but hardly a smoking gun. Zicam will have to sell more than $16M a year to get that kind of validation. Moreover, I don't think they get there alone... I think it is safe to say that thus far sales have failed to meet lofty bullish expectations. It is equally safe to say that a 49% increase this year after an even larger increase last year was far more than the bearish contingent was presaging. I like to think that investors learned some lessons from the bubble, but every interaction I have with Dan leads me to think that this is probably not the case. I haven't heard Dan make any wild valuation projections lately. Doesn't mean he has to buy into mad2's $18-24M proffering.

To: Mark Marcellus who wrote (4098)	3/12/2002 7:13:14 PM
From: DanZ	Read Replies (1) \| Respond to of 5582

<Dan's dark hints that the company might soon return to selling its only successful product give me some hopes on this score.> Either I don't understand what you meant by the above or you misinterpreted what I meant. I don't think that Gum Tech will sell Zicam. I think that they will partner with a large company, and believe that this is what Mr. Johnson eluded to in the last press release. If they partner with a large company, I think it will be very positive for domestic and international sales, and the company's stock price.

To: Mark Marcellus who wrote (4098)	3/14/2002 3:44:26 AM
From: DanZ	Respond to of 5582

Well, Mark it's obvious why I misunderstood what you meant. You wrote "Dan's dark hints that the company might soon return to selling its only successful product give me some hopes on this score." I don't consider Gum Tech's stock a product, and even if I did, I wouldn't consider it their only successful product. While Zicam hasn't been as successful as I would have liked as quickly as I would have liked, I believe that it will be very successful in time. Tonight's news will help in that regard. Gum Tech International's Zicam Cold Remedy to Be The Subject of Upcoming Scientific Presentation PHOENIX, March 13 /PRNewswire-FirstCall/ -- Gum Tech International Inc. (Nasdaq: GUMM - news), developer and distributor of Zicam® Cold Remedy and Zicam® Allergy Relief, announced today that the cold remedy will be the subject of an upcoming scientific presentation by Sherif Beniameen Mossad, M.D., F.A.C.P., F.I.D.S.A. at the 10th International Congress of Infectious Diseases (ICID) taking place in Singapore this week. During a poster session at the conference, Dr. Mossad, of the Department of Infectious Diseases at the Cleveland Clinic Foundation, will present the results of a new clinical study designed to specifically measure the effects of a zincum gluconicum nasal gel (Zicam Cold Remedy) on patients identified as having rhinovirus. The study results are currently undergoing peer review as a preliminary to possible publication in a professional journal. The study was funded by Gum Tech International, Inc. biz.yahoo.com I think it is is fair to conclude that Dr. Mossad isn't going to Singapore to present negative results. Let's put a few things together. Here are two quotes from the 2/28/2002 press release. "Increase the presence of the company in the financial marketplace and pursue aggressive expansion of the company's shareholder base with the advice of an investor relations firm recently retained by the company." "We are well-positioned to pursue expansion of complementary product lines and distribution channels, both domestically and abroad, and we are in the process of further strengthening the base of the company through strategic alliances and new product development" How do you think a positive presentation at ICID plays into these two quotes? Do you think C & A will have an easy time getting new investors interested in GUMM if the results of Dr. Mossad's study are positive? Do you think a positive result has something to do with a strategic alliance for Zicam? I note in particular that Dr. Mousad's study was "designed to specifically measure the effects of a zincum gluconicum nasal gel (Zicam Cold Remedy) on patients identified as having rhinovirus." If his method is irrefutable, the study should squelch criticism that some people in the medical community had with Dr. Hirt's study. As for tweaking me, you're wasting your time. I'm sorry to break this to you, but I don't tweak easily and you haven't ever tweaked me.